Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
Authors
Keywords
-
Journal
HYPERTENSION RESEARCH
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-26
DOI
10.1038/s41440-018-0187-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects
- (2018) Manabu Kato et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Independent regulation of renin–angiotensin–aldosterone system in the kidney
- (2018) Akira Nishiyama et al. Clinical and Experimental Nephrology
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure
- (2018) Hui Pei et al. MEDICINE
- Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease
- (2018) Akira Nishiyama HYPERTENSION RESEARCH
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- A high-salt diet enhances leukocyte adhesion in association with kidney injury in young dahl salt-sensitive rats
- (2017) Hidenori Takahashi et al. HYPERTENSION RESEARCH
- Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
- (2017) Takuo Yoshimoto et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats
- (2017) Lei Li et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension
- (2016) Shigeru Shibata et al. HYPERTENSION RESEARCH
- Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy
- (2016) Danijela Karanovic et al. PLoS One
- Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
- (2016) Makiko Yamada et al. XENOBIOTICA
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy
- (2015) Atsuhisa Sato HYPERTENSION RESEARCH
- Mineralocorticoid receptor activation as an etiological factor in kidney diseases
- (2013) Kohei Ueda et al. Clinical and Experimental Nephrology
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study
- (2013) Kazuaki Shimamoto et al. HYPERTENSION RESEARCH
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- (2013) Paul A. James et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Oxidative Stress-Induced Glomerular Mineralocorticoid Receptor Activation Limits the Benefit of Salt Reduction in Dahl Salt-Sensitive Rats
- (2012) Kento Kitada et al. PLoS One
- Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor–dependent pathway
- (2011) Shigeru Shibata et al. JOURNAL OF CLINICAL INVESTIGATION
- Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovasucular events
- (2010) Genjiro Kimura et al. HYPERTENSION RESEARCH
- Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats
- (2010) H. Kawarazaki et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of mineralocorticoid receptor blockade on the renal renin–angiotensin system in Dahl salt-sensitive hypertensive rats
- (2009) Aoshuang Zhu et al. JOURNAL OF HYPERTENSION
- Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats
- (2009) A. Nishiyama et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease
- (2008) Shigeru Shibata et al. NATURE MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started